Impact of a mixed bacterial lysate (OM-85 BV) on the immunogenicity, safety and tolerability of inactivated influenza vaccine in children with recurrent respiratory tract infection

Susanna Esposito, Paola Marchisio, Elisabetta Prada, Cristina Daleno, Laura Porretti, Rita Carsetti, Annalisa Bosco, Valentina Ierardi, Alessia Scala, Nicola Principi

Research output: Contribution to journalArticle

Abstract

It is known that the immunogenicity and efficacy of conventional inactivated influenza vaccines (IIVs) are not completely satisfactory in children. The aim of this prospective, randomised, single-blind study was to compare the immune response to, and the effectiveness and safety of, an IIV (Fluarix, GlaxoSmithKline Biologicals, Rixensart, Belgium) administered to 68 children aged 36-59 months affected by recurrent respiratory tract infections (RRTIs) who were vaccinated with (n= 33) or without (n= 35) the mixed bacterial lysate OM-85 BV (Broncho-vaxom, Vifor Pharma, Geneva, Switzerland). OM-85 BV had no effect on seroconversion or seroprotection rates, geometric mean titres, or dendritic cells, which were not significantly different between the two groups. Moreover, OM-85 BV did not significantly increase the pool of the memory B cells that produce IgG and IgM antibodies against the influenza antigens. However, respiratory morbidity was significantly lower in the children treated with OM-85 BV (p

Original languageEnglish
Pages (from-to)2546-2552
Number of pages7
JournalVaccine
Volume32
Issue number22
DOIs
Publication statusPublished - May 7 2014

Fingerprint

Inactivated Vaccines
Influenza Vaccines
Respiratory Tract Infections
influenza
respiratory tract diseases
immune response
vaccines
Safety
seroconversion
dendritic cells
Belgium
Switzerland
B-lymphocytes
morbidity
antigens
Single-Blind Method
antibodies
Dendritic Cells
Human Influenza
Immunoglobulin M

Keywords

  • Bacterial lysate
  • Children
  • Influenza
  • Influenza vaccine
  • OM-85 BV
  • Recurrent respiratory tract infection

ASJC Scopus subject areas

  • Immunology and Microbiology(all)
  • Infectious Diseases
  • Public Health, Environmental and Occupational Health
  • veterinary(all)
  • Molecular Medicine

Cite this

Impact of a mixed bacterial lysate (OM-85 BV) on the immunogenicity, safety and tolerability of inactivated influenza vaccine in children with recurrent respiratory tract infection. / Esposito, Susanna; Marchisio, Paola; Prada, Elisabetta; Daleno, Cristina; Porretti, Laura; Carsetti, Rita; Bosco, Annalisa; Ierardi, Valentina; Scala, Alessia; Principi, Nicola.

In: Vaccine, Vol. 32, No. 22, 07.05.2014, p. 2546-2552.

Research output: Contribution to journalArticle

Esposito, Susanna ; Marchisio, Paola ; Prada, Elisabetta ; Daleno, Cristina ; Porretti, Laura ; Carsetti, Rita ; Bosco, Annalisa ; Ierardi, Valentina ; Scala, Alessia ; Principi, Nicola. / Impact of a mixed bacterial lysate (OM-85 BV) on the immunogenicity, safety and tolerability of inactivated influenza vaccine in children with recurrent respiratory tract infection. In: Vaccine. 2014 ; Vol. 32, No. 22. pp. 2546-2552.
@article{7e74007e52bc472d9b28310ff2b9ec49,
title = "Impact of a mixed bacterial lysate (OM-85 BV) on the immunogenicity, safety and tolerability of inactivated influenza vaccine in children with recurrent respiratory tract infection",
abstract = "It is known that the immunogenicity and efficacy of conventional inactivated influenza vaccines (IIVs) are not completely satisfactory in children. The aim of this prospective, randomised, single-blind study was to compare the immune response to, and the effectiveness and safety of, an IIV (Fluarix, GlaxoSmithKline Biologicals, Rixensart, Belgium) administered to 68 children aged 36-59 months affected by recurrent respiratory tract infections (RRTIs) who were vaccinated with (n= 33) or without (n= 35) the mixed bacterial lysate OM-85 BV (Broncho-vaxom, Vifor Pharma, Geneva, Switzerland). OM-85 BV had no effect on seroconversion or seroprotection rates, geometric mean titres, or dendritic cells, which were not significantly different between the two groups. Moreover, OM-85 BV did not significantly increase the pool of the memory B cells that produce IgG and IgM antibodies against the influenza antigens. However, respiratory morbidity was significantly lower in the children treated with OM-85 BV (p",
keywords = "Bacterial lysate, Children, Influenza, Influenza vaccine, OM-85 BV, Recurrent respiratory tract infection",
author = "Susanna Esposito and Paola Marchisio and Elisabetta Prada and Cristina Daleno and Laura Porretti and Rita Carsetti and Annalisa Bosco and Valentina Ierardi and Alessia Scala and Nicola Principi",
year = "2014",
month = "5",
day = "7",
doi = "10.1016/j.vaccine.2014.03.055",
language = "English",
volume = "32",
pages = "2546--2552",
journal = "Vaccine",
issn = "0264-410X",
publisher = "Elsevier BV",
number = "22",

}

TY - JOUR

T1 - Impact of a mixed bacterial lysate (OM-85 BV) on the immunogenicity, safety and tolerability of inactivated influenza vaccine in children with recurrent respiratory tract infection

AU - Esposito, Susanna

AU - Marchisio, Paola

AU - Prada, Elisabetta

AU - Daleno, Cristina

AU - Porretti, Laura

AU - Carsetti, Rita

AU - Bosco, Annalisa

AU - Ierardi, Valentina

AU - Scala, Alessia

AU - Principi, Nicola

PY - 2014/5/7

Y1 - 2014/5/7

N2 - It is known that the immunogenicity and efficacy of conventional inactivated influenza vaccines (IIVs) are not completely satisfactory in children. The aim of this prospective, randomised, single-blind study was to compare the immune response to, and the effectiveness and safety of, an IIV (Fluarix, GlaxoSmithKline Biologicals, Rixensart, Belgium) administered to 68 children aged 36-59 months affected by recurrent respiratory tract infections (RRTIs) who were vaccinated with (n= 33) or without (n= 35) the mixed bacterial lysate OM-85 BV (Broncho-vaxom, Vifor Pharma, Geneva, Switzerland). OM-85 BV had no effect on seroconversion or seroprotection rates, geometric mean titres, or dendritic cells, which were not significantly different between the two groups. Moreover, OM-85 BV did not significantly increase the pool of the memory B cells that produce IgG and IgM antibodies against the influenza antigens. However, respiratory morbidity was significantly lower in the children treated with OM-85 BV (p

AB - It is known that the immunogenicity and efficacy of conventional inactivated influenza vaccines (IIVs) are not completely satisfactory in children. The aim of this prospective, randomised, single-blind study was to compare the immune response to, and the effectiveness and safety of, an IIV (Fluarix, GlaxoSmithKline Biologicals, Rixensart, Belgium) administered to 68 children aged 36-59 months affected by recurrent respiratory tract infections (RRTIs) who were vaccinated with (n= 33) or without (n= 35) the mixed bacterial lysate OM-85 BV (Broncho-vaxom, Vifor Pharma, Geneva, Switzerland). OM-85 BV had no effect on seroconversion or seroprotection rates, geometric mean titres, or dendritic cells, which were not significantly different between the two groups. Moreover, OM-85 BV did not significantly increase the pool of the memory B cells that produce IgG and IgM antibodies against the influenza antigens. However, respiratory morbidity was significantly lower in the children treated with OM-85 BV (p

KW - Bacterial lysate

KW - Children

KW - Influenza

KW - Influenza vaccine

KW - OM-85 BV

KW - Recurrent respiratory tract infection

UR - http://www.scopus.com/inward/record.url?scp=84898546522&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84898546522&partnerID=8YFLogxK

U2 - 10.1016/j.vaccine.2014.03.055

DO - 10.1016/j.vaccine.2014.03.055

M3 - Article

C2 - 24681270

AN - SCOPUS:84898546522

VL - 32

SP - 2546

EP - 2552

JO - Vaccine

JF - Vaccine

SN - 0264-410X

IS - 22

ER -